## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($312.23)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 2, Bearish: 6)

**1. Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets**
- Source: ts2.tech | 20251203T010202 | Neutral | Relevance: 100%
- This article provides an in-depth outlook on Elevance Health (ELV) stock as of December 2025, following its Q3 earnings beat. It details the company's financial performance, stock valuation, and ongoing legal and regulatory challenges, including Medicare Advantage star ratings disputes and securities lawsuits. The report also highlights new analyst targets, institutional buying, and key risks and opportunities for investors considering ELV for 2026 and beyond.

**2. $12.88M Anthem mental health treatment class action settlement**
- Source: Class Action Lawsuits | 20251202T175108 | Bearish | Relevance: 100%
- Anthem (now Elevance Health) has agreed to a $12.875 million class action settlement to resolve claims that it improperly denied mental health and substance use disorder treatment based on overly restrictive medical necessity guidelines. Individuals whose coverage requests for residential treatment services for a behavioral health disorder were denied by Anthem since April 29, 2017, based on specific guidelines may be eligible for reimbursement of out-of-pocket expenses or a $100 nominal payment. Claims must be filed by January 20, 2026.

**3. Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation**
- Source: KTLA | 20251202T110000 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Elevance Health, Inc. (NYSE: ELV) on behalf of investors who purchased securities prior to April 18, 2024. The investigation aims to determine if Elevance and its officers/directors engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information and to assist in the investigation, offering representation on a contingency fee basis.

**4. North Peak Capital Management LLC Purchases 115,460 Shares of Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251202T020915 | Bullish | Relevance: 100%
- North Peak Capital Management LLC boosted its stake in Elevance Health, Inc. by 40.3% in the second quarter, acquiring an additional 115,460 shares, bringing its total to 401,670 shares valued at approximately $156.23 million. This makes Elevance Health the fourth-largest position in North Peak's portfolio, representing 12.3% of its investments. Elevance Health reported strong earnings with $6.03 EPS, exceeding consensus estimates, and declared a quarterly dividend of $1.71 per share.

**5. Mackenzie Financial Corp Grows Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251203T041012 | Bullish | Relevance: 100%
- Mackenzie Financial Corp significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 40.9% in Q2, acquiring an additional 21,193 shares, bringing their total holdings to 73,037 shares valued at $28.41 million. This increase comes as Elevance Health exceeded earnings expectations in its most recent quarter, reporting $6.03 EPS against an anticipated $5.03, and analysts maintain a "Hold" rating with a consensus target price of $398.44.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |
| 2025-11-04 | Mizuho | $400 | $420 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |
| 2025-11-04 | Mizuho | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 8.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $78.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 12.3 |
| Current P/E | 11.0 |
| YoY Growth | -10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.5% to -0.0% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.0pp (needs >4.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (1.43), confirming momentum. RSI neutral at 52. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.03% (CS: 52) | Neutral |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | 1.43 | Bullish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 0.920x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $330.75
- **Stop Loss:** $312.23 (5.6% risk)
- **Target:** $367.79 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $16,868.25
- **Portfolio %:** 16.87%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*